Brain Tech is Here
Neurotechnology Leaves the Nest but Waits for Policy Push
There’s no mistaking the progress. Neurotechnology—the tools to treat and understand the brain and nervous system—holds the potential to transform nearly every aspect of our lives and revolutionize our conception of the human mind.
Imagine walking into a doctor’s office where an advanced brain scanning system can detect cellular-level changes that signal the onset of Alzheimer’s disease, years before any physical or mental symptoms manifest. You and your loved ones’ quality of life could then be extended by decades with a treatment plan personalized to your specific case. Today, brain imaging technologies such as this are only just beginning to illuminate the causes of brain-related illnesses. But a wide chasm must still be crossed if we are to develop effective treatments for the nearly 100 million Americans and 2 billion people worldwide that currently suffer from brain illnesses such as Alzheimer’s.
The annual national economic burden of brain-related disorders has reached over $1 trillion (see chart) and is growing alarmingly due to an aging population. While research into the brain and brain-related illnesses is moving forward more rapidly than any other science today, our understanding of how the brain works still has many gaps and our ability to repair damage remains limited. Critical unmet medical needs exist in almost every area of brain and nervous system disorders, including Alzheimer’s disease, addiction, anxiety, autism, depression, epilepsy, multiple sclerosis, obesity, Parkinson’s disease, pain, sensory disorders, spinal cord injury, stroke, schizophrenia, sleep disorders, and traumatic brain injury.
Investigation into the mechanisms and functions of the brain will lead to vastly improved understanding of brain disease and injuries, human cognition and behavior, and will give us an unprecedented ability to treat and heal those in need, as well as begin to reduce this growing burden on our economy. But all of this won’t happen on its own.
Emerging neurotech companies developing drugs, medical devices, or diagnostics for the brain and nervous system face more difficult investment requirements, research and development challenges, and regulatory milestones than other healthcare sectors. This additional complexity results in higher costs and longer time to market for many neurotech treatments. For example, it costs nearly $100 million more and takes two years longer to bring a neuropharmaceutical treatment to market than the average drug.
It is critical that the progressive traditions of American science and technology, especially our longstanding focus on the legal and ethical implications of new scientific discoveries, carry special weight as this new science matures.While some companies can get private funding to bring low-risk drugs to market, few risk-averse private investors will fund research into potentially more powerful treatments leveraging novel approaches like gene therapy for Alzheimer’s or neurostimulation for mental illnesses. Today, the potential for innovative treatments has never been higher—but brain researchers and neurotech entrepreneurs require additional support if they are to bring their ideas out of the labs and into patients’ lives.
A targeted, coordinated national effort is needed to support the development of neurotechnology across the board. It is vitally important that public infrastructure be developed to ensure that today’s neurotechnology discoveries quickly become tools to improve the human condition. Government must become a partner with the private sector to encourage the translation of brain research into treatments.
In an effort to improve national coordination and accelerate neurotech innovation, the Neurotechnology Industry Organization is spearheading the National Neurotechnology Initiative. The NNTI calls for establishing a National Neurotechnology Coordinating Office within the Department of Health and Human Services to help agencies plan joint and complementary research strategies and to serve as the unified voice of federal neurotechnology efforts. The new initiative also seeks to create an advisory panel of experts from industry, academic institutions, and non-profit organizations to inform the new office on issues including research and development priorities, technology transfer, commercial applications, and ethical, legal, and social issues.
The NNTI legislation, which is currently being evaluated by healthcare policymakers on Capitol Hill, includes $200 million in new federal funding for the first fiscal year. This funding would flow to the National Institutes of Health, the Food and Drug Administration and several other agencies to jumpstart new research, prepare the regulatory ground for consideration of new neurotechnology tools, and examine the ethical, legal, and social implications of this new field.
Under our proposal, the National Institutes of Health would receive funds to coordinate research and move that research out of government labs and into young innovative companies developing the next generation of neurotech treatments. The FDA would be able to hire neuroscience-related staff and develop workshops to create more robust neurotech standards to ensure the increased timeliness and safety of the neurotechnology review process.
Like previous successful models of coordinated federal investment initiatives, including the Human Genome Project and the National Nanotechnology Initiative, the National Neurotechnology Initiative will lead to a cascade of investment, discovery, applications, and benefits that can only be imagined today. At the same time, a federal research effort can help ensure the responsible development of neurotechnology by establishing ethical guidelines and policy for research, development, and applications.
By taking these steps Congress can ensure that the United States remains at the forefront of the race to uncover the workings of the mind. Huge economic payoffs will accrue to new and emerging centers of neurotechnology excellence around our nation, among them the San Francisco Bay area, Boston, San Diego, Seattle and Greater New York. The growth of strong neurotech regions will have long-lasting implications for employment, infrastructure development, and regional competitiveness.
Today the United States leads the world in neurotechnology R and D and commercialization, but the United Kingdom, China, Sweden, Japan, and Germany are all developing their own centers of neurotechnology excellence. The global expansion of knowledge in this new scientific arena is good for the United States and good for humanity. Yet it is critical that the progressive traditions of American science and technology, especially our longstanding focus on the legal and ethical implications of new scientific discoveries, carry special weight as this new science matures.
Neurotechnology applications have the potential to transform highly specialized areas of medicine, computing, and defense, and will also affect the everyday lives of Americans. How this plays out, and the benefits or consequences of these new tools, will depend on the U.S. government taking a leadership role in neurotechnology R and D. As Congress weighs our legislative proposals, we invite the broader scientific community to examine our proposal and support this important cross-disciplinary initiative.
Zack Lynch is Executive Director of the Neurotechnology Industry Organization.
Comments on this article